Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2019

01-10-2019 | Special Article

Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements

Authors: Noam Yarom, Allan Hovan, Paolo Bossi, Anura Ariyawardana, Siri Beier Jensen, Margherita Gobbo, Hanan Saca-Hazboun, Abhishek kandwal, Alessandra Majorana, Giulia Ottaviani, Monica Pentenero, Narmin Mohammed Nasr, Tanya Rouleau, Anna Skripnik Lucas, Nathaniel Simon Treister, Eyal Zur, Vinisha Ranna, Anusha Vaddi, Karis Kin Fong Cheng, Andrei Barasch, Rajesh V. Lalla, Sharon Elad, On behalf of The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO)

Published in: Supportive Care in Cancer | Issue 10/2019

Login to get access

Abstract

Purpose

To update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of oral mucositis (OM).

Methods

A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible.

Results

A total of 78 papers were identified within the scope of this section, out of which 29 were included in this part, and were analyzed with 27 previously reviewed studies. A new Suggestion was made for oral glutamine for the prevention of OM in head and neck (H&N) cancer patients receiving radiotherapy with concomitant chemotherapy. The previous Recommendation against the use of parenteral glutamine for the prevention of OM in hematopoietic stem cell transplantation (HSCT) patients was re-established. A previous Suggestion for zinc to prevent OM in H&N cancer patients treated with radiotherapy or chemo-radiotherapy was reversed to No Guideline Possible. No guideline was possible for other interventions.

Conclusions

Of the vitamins, minerals, and nutritional supplements studied for the management of OM, the evidence supports a Recommendation against parenteral glutamine in HSCT patients and a Suggestion in favor of oral glutamine in H&N cancer patients for the management of OM.
Literature
1.
Elad S, Zadik Y, Yarom N (2017) Oral complications of nonsurgical cancer therapies. Atlas Oral Maxillofac Surg Clin North Am 25:133–147PubMedCrossRef
2.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, Mucositis study section of the Multinational Association of Supportive Care in C, the International Society for Oral O (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
3.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, Mucositis study section of the Multinational Association for Supportive Care in C, International Society for Oral O (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046PubMedCrossRef
4.
Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in C, International Society of Oral O (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461PubMedCrossRef
5.
Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, Hovan A, Yarom N, Lalla RV, Bowen J, Elad S, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral O (2013) Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer 21:3223–3232PubMedCrossRef
6.
Yarom N, Ariyawardana A, Hovan A, Barasch A, Jarvis V, Jensen SB, Zadik Y, Elad S, Bowen J, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral O (2013) Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer 21:3209–3221PubMedCrossRef
7.
Ranna V, Cheng K, Castillo D, Porcello L, Vaddi A, Lalla R, Bossi P, Elad S (2019) Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: an overview of the methods. Support Care Cancer
8.
Somerfield M, Padberg J, Pfister D, Bennett C, Recht A, Smith T, Weeks J, Winn R, Durant J (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments 4:881–886
9.
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754PubMedCrossRef
10.
Ertekin MV, Koc M, Karslioglu I, Sezen O (2004) Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 58(1):167–174PubMedCrossRef
11.
Doi H, Fujiwara M, Suzuki H, Niwa Y, Nakayama M, Shikata T, Odawara S, Takada Y, Kimura T, Kamikonya N, Hirota S (2015) Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol Clin Oncol 3:381–386PubMedCrossRef
12.
Suzuki A, Kobayashi R, Shakui T, Kubota Y, Fukita M, Kuze B, Aoki M, Sugiyama T, Mizuta K, Itoh Y (2016) Effect of polaprezinc on oral mucositis, irradiation period, and time to discharge in patients with head and neck cancer. Head Neck 38:1387–1392PubMedCrossRef
13.
Lin LC, Que J, Lin LK, Lin FC (2006) Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys 65:745–750PubMedCrossRef
14.
Lin YS, Lin LC, Lin SW, Chang CP (2010) Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study. Nutr Cancer 62:682–691PubMedCrossRef
15.
Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y (2010) Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer 127:1984–1990PubMedCrossRef
16.
Sangthawan D, Phungrassami T, Sinkitjarurnchai W (2013) A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients. J Med Assoc 96:69–76
17.
Gorgu SZ, Ilknur AF, Sercan O, Rahsan H, Nalan A (2013) The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer. Int J Radiat Res 11:111–116
18.
Moslemi D, Babaee N, Damavandi M, Pourghasem M, Moghadamnia AA (2014) Oral zinc sulphate and prevention of radiation-induced oropharyngeal mucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial. Int J Radiat Res 12:235–241
19.
Mansouri A, Hadjibabaie M, Iravani M, Shamshiri AR, Hayatshahi A, Javadi MR, Khoee SH, Alimoghaddam K, Ghavamzadeh A (2012) The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. Hematol Oncol 30:22–26PubMedCrossRef
20.
Hayashi H, Kobayashi R, Suzuki A, Ishihara M, Nakamura N, Kitagawa J, Kanemura N, Kasahara S, Kitaichi K, Hara T, Tsurumi H, Moriwaki H, Itoh Y (2014) Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res 34:7271–7277PubMed
21.
Arbabi-kalati F, Arbabi-kalati F, Deghatipour M, Ansari Moghadam A (2012) Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch Iran Med 15:413–417PubMed
22.
Mehdipour M, Taghavi Zenoz A, Asvadi Kermani I, Hosseinpour A (2011) A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis. Daru 19:71–73PubMedPubMedCentral
23.
Bhatt N, Naithani R, Gupta SK (2017) Supersaturated calcium phosphate rinse in prevention and treatment of mucositis in patients undergoing hematopoietic stem. Cell Transplant Exp Clin Transplant 15:567–570PubMed
24.
Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB (2003) A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31:705–712PubMedCrossRef
25.
Wasko-Grabowska A, Rzepecki P, Oborska S, Barzal J, Mlot B, Gawronski K, Wasko M, Szczylik C (2012) A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience. J BUON 17:363–368PubMed
26.
Wasko-Grabowska A, Rzepecki P, Oborska S, Barzal J, Gawronski K, Mlot B, Szczylik C (2011) Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. Transplant Proc 43:3111–3113PubMedCrossRef
27.
Markiewicz M, Dzierzak-Mietla M, Frankiewicz A, Zielinska P, Koclega A, Kruszelnicka M, Kyrcz-Krzemien S (2012) Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer 20:2223–2229PubMedPubMedCentralCrossRef
28.
Svanberg A, Ohrn K, Birgegard G (2015) Caphosol((R)) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur J Oncol Nurs 19:50–53PubMedCrossRef
29.
Raphael MF, den Boer AM, Kollen WJ, Mekelenkamp H, Abbink FC, Kaspers GJ, Zomer-Kooijker K, Molmans BH, Tissing WJ (2014) Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?: results from a prospective multicenter double blind randomized controlled trial. Support Care Cancer 22:3–6PubMedCrossRef
30.
Lambrecht M, Mercier C, Geussens Y, Nuyts S (2013) The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care. Support Care Cancer 21:2663–2670PubMedCrossRef
31.
Stokman MA, Burlage FR, Spijkervet FK (2012) The effect of a calcium phosphate mouth rinse on (chemo) radiation induced oral mucositis in head and neck cancer patients: a prospective study. Int J Dent Hyg 10:175–180PubMedCrossRef
32.
Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef
33.
34.
Yildirim ZK, Bidev D, Buyukavci M (2013) Parenteral glutamine supplementation has no effect on chemotherapy-induced toxicity in children with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 35:371–376PubMedCrossRef
35.
van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP (1994) Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 74(10):2879–2884 1994 Nov 15 74: 2879-2884PubMedCrossRef
36.
Kuskonmaz B, Yalcin S, Kucukbayrak O, Cetin N, Cetin M, Tezcan I, Uckan D (2008) The effect of glutamine supplementation on hematopoietic stem cell transplant outcome in children: a case-control study. Pediatr Transplant 12(1):47–51PubMedCrossRef
37.
Schloerb PR, Skikne BS (1999) Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr 23:117–122PubMedCrossRef
38.
Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, Kozak T (2002) Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant 30:953–961PubMedCrossRef
39.
Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M, Rutella S, Cicconi S, Fiorini A, D'Onofrio G, Leone G, Sica S (2003) Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 88:192–200PubMed
40.
Blijlevens NM, Donnelly JP, Naber AH, Schattenberg AV, DePauw BE (2005) A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer 13:790–796PubMedCrossRef
41.
Uderzo C, Rebora P, Marrocco E, Varotto S, Cichello F, Bonetti M, Maximova N, Zanon D, Fagioli F, Nesi F, Masetti R, Rovelli A, Rondelli R, Valsecchi MG, Cesaro S (2011) Glutamine-enriched nutrition does not reduce mucosal morbidity or complications after stem-cell transplantation for childhood malignancies: a prospective randomized study. Transplantation 91:1321–1325PubMedCrossRef
42.
Anderson PM, Ramsay NK, Shu XO, Rydholm N, Rogosheske J, Nicklow R, Weisdorf DJ, Skubitz KM (1998) Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22(4):339–344PubMedCrossRef
43.
Cockerham MB, Weinberger BB, Lerchie SB (2000) Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 34(3):300–303PubMedCrossRef
44.
Iyama S, Sato T, Tatsumi H, Hashimoto A, Tatekoshi A, Kamihara Y, Horiguchi H, Ibata S, Ono K, Murase K, Takada K, Sato Y, Hayashi T, Miyanishi K, Akizuki E, Nobuoka T, Mizugichi T, Takimoto R, Kobune M, Hirata K, Kato J (2014) Efficacy of enteral supplementation enriched with glutamine, fiber, and oligosaccharide on mucosal injury following hematopoietic stem cell transplantation. Case Rep Oncol 7:692–699PubMedPubMedCentralCrossRef
45.
Coghlin Dickson TM, Wong RM, Offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE (2000) Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J Parenter Enteral Nutr 24(2):61–66PubMedCrossRef
46.
Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, Jackson GB, Sandler ES (2005) A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 36(7):611–616PubMedCrossRef
47.
Chattopadhyay S, Saha A, Azam M, Mukherjee A, Sur PK (2014) Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: a prospective randomized study. South Asian J Cancer 3:8–12PubMedPubMedCentralCrossRef
48.
Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H, Uejima E, Ito T (2015) L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep 33:33–39PubMedCrossRef
49.
Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC, Hsiung CY (2000) Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46(3):535–539PubMedCrossRef
50.
Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P (2008) Pilot study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res 36(6):1383–1391PubMedCrossRef
51.
Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, Allgar V, Bowers D, Picton SV (2009) The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 63(1):134–140PubMedCrossRef
52.
Peterson DE, Jones JB, Petit RG (2007) 2nd Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109(2):322–331PubMedCrossRef
53.
Skubitz KM, Anderson PM (1996) Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 127(2):223–228PubMedCrossRef
54.
Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS (1998) Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg 227(5):772–778; discussion 778-80PubMedPubMedCentralCrossRef
55.
Anderson PM, Schroeder G, Skubitz KM (1998) Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83:1433–1439PubMedCrossRef
56.
Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, Shelley MD, Elia M (1994) 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 70:732–735PubMedPubMedCentralCrossRef
57.
Choi K, Lee SS, Oh SJ, Lim SY, Jeon WK, Oh TY, Kim JW (2007) The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 26:57–62PubMedCrossRef
58.
Morishita T, Tsushita N, Imai K, Sakai T, Miyao K, Sakemura R, Kato T, Niimi K, Ono Y, Sawa M (2016) The efficacy of an Oral elemental diet in patients undergoing hematopoietic stem cell transplantation. Intern Med 55:3561–3569PubMedPubMedCentralCrossRef
59.
Tanaka Y, Takahashi T, Yamaguchi K, Osada S, Shimokawa T, Yoshida K (2016) Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study. Support Care Cancer 24:933–941PubMedCrossRef
60.
Ogata Y, Ishibashi N, Yamaguchi K, Uchida S, Kamei H, Nakayama G, Hirakawa H, Tanigawa M, Akagi Y (2016) Preventive effects of amino-acid-rich elemental diet Elental(R) on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. Support Care Cancer 24:783–789PubMedCrossRef
61.
Harada K, Ferdous T, Horinaga D, Uchida K, Mano T, Mishima K, Park S, Hanazawa H, Takahashi S, Okita A, Fukunaga M, Maruta J, Kami N, Shibuya K, Ueyama Y (2016) Efficacy of elemental diet on prevention for chemoradiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma. Support Care Cancer 24:953–959PubMedCrossRef
62.
Galli F, Azzi A, Birringer M, Cook-Mills JM, Eggersdorfer M, Frank J, Cruciani G, Lorkowski S, Ozer NK (2017) Vitamin E: emerging aspects and new directions. Free Radic Biol Med 102:16–36PubMedCrossRef
63.
Khurana H, Pandey RK, Saksena AK, Kumar A (2013) An evaluation of vitamin E and pycnogenol in children suffering from oral mucositis during cancer chemotherapy. Oral Dis 19:456–464PubMedCrossRef
64.
Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A (1992) Cohen MH vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 92(5):481–484PubMedCrossRef
65.
Sung L, Tomlinson GA, Greenberg ML, Koren G, Judd P, Ota S, Feldman BM (2007) Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer 43(8):1269–1275PubMedCrossRef
66.
Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, Ilha L (2004) Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26(4):313–321PubMedCrossRef
67.
El-Housseiny AA, Saleh SM, El-Masry AA, Allam AA (2007) The effectiveness of vitamin “E” in the treatment of oral mucositis in children receiving chemotherapy. J Clin Pediatr Dent 31:167–170PubMedCrossRef
68.
Ryan-Harshman M, Aldoori W (2005) The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. Can J Diet Pract Res 66:98–102PubMedCrossRef
69.
Jahangard-Rafsanjani Z, Gholami K, Hadjibabaie M, Shamshiri AR, Alimoghadam K, Sarayani A, Mojtahedzadeh M, Ostadali-Dehaghi M, Ghavamzadeh A (2013) The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial. Bone Marrow Transplant 48:832–836PubMedCrossRef
70.
Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, Shono Y, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M (2012) Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant 47:258–264PubMedCrossRef
71.
Hamidieh AA, Sherafatmand M, Mansouri A, Hadjibabaie M, Ashouri A, Jahangard-Rafsanjani Z, Gholami K, Javadi MR, Ghavamzadeh A, Radfar M (2016) Calcitriol for oral mucositis prevention in patients with Fanconi anemia undergoing hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Am J Ther 23:e1700–e1708PubMedCrossRef
72.
Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703PubMedCrossRef
73.
Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80:1678S–1688SPubMedCrossRef
74.
Chitapanarux I, Pisprasert V, Tharavichitkul E, Jakrabhandu S, Klunklin P, Onchan W, Supawongwattana B, Traisathit P, Rattanachaiwong S, Sattasiri WM (2016) Randomized study of nutritional status and treatment toxicities of oral arginine, glutamine, and omega-3 fatty acids during concurrent chemoradiotherapy for head and neck cancer patients. Funct Foods Health Dis 6:121–132CrossRef
75.
Pattanayak L, Panda N, Dash MK, Mohanty S, Samantaray S (2016) Management of chemoradiation-induced mucositis in head and neck cancers with oral glutamine. J Glob Oncol 2:200–206PubMedPubMedCentralCrossRef
76.
Lopez-Vaquero D, Gutierrez-Bayard L, Rodriguez-Ruiz JA, Saldana-Valderas M, Infante-Cossio P (2017) Double-blind randomized study of oral glutamine on the management of radio/chemotherapy-induced mucositis and dermatitis in head and neck cancer. Mol Clin Oncol 6:931–936PubMedPubMedCentralCrossRef
77.
Pachon Ibanez J, Pereira Cunill JL, Osorio Gomez GF, Irles Rocamora JA, Serrano Aguayo P, Quintana Angel B, Fuentes Pradera J, Chaves Conde M, Ortiz Gordillo MJ, Garcia Luna PP (2018) Prevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine. Nutr Hosp 35:428–433PubMed
78.
Nihei S, Sato J, Komatsu H, Ishida K, Kimura T, Tomita T, Kudo K (2018) The efficacy of sodium azulene sulfonate L-glutamine for managing chemotherapy-induced oral mucositis in cancer patients: a prospective comparative study. J Pharm Health Care Sci 4:20PubMedPubMedCentralCrossRef
79.
Okada T, Nakajima Y, Nishikage T, Ryotokuji T, Miyawaki Y, Hoshino A, Tokairin Y, Kawada K, Nagai K, Kawano T (2017) A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. Asia Pac J Clin Nutr 26:42–48PubMed
80.
Ishikawa T, Yasuda T, Doi T, Okayama T, Sakamoto N, Gen Y, Dohi O, Yoshida N, Kamada K, Uchiyama K, Handa O, Takagi T, Konishi H, Yagi N, Kokura S, Naito Y, Itoh Y (2016) The amino acid-rich elemental diet Elental(R) preserves lean body mass during chemo- or chemoradiotherapy for esophageal cancer. Oncol Rep 36:1093–1100PubMedCrossRef
81.
Rambod M, Pasyar N, Ramzi M (2018) The effect of zinc sulfate on prevention, incidence, and severity of mucositis in leukemia patients undergoing chemotherapy. Eur J Oncol Nurs 33:14–21PubMedCrossRef
82.
Hayashi H, Kobayashi R, Suzuki A, Yamada Y, Ishida M, Shakui T, Kitagawa J, Hayashi H, Sugiyama T, Takeuchi H, Tsurumi H, Itoh Y (2016) Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy. Med Oncol 33:7CrossRef
83.
Wong KH, Kuciejewska A, Sharabiani MTA, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL (2017) A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol 122:207–211PubMedCrossRef
84.
Treister N, Nieder M, Baggott C, Olson E, Chen L, Dang H, Krailo M, August A, Sung L (2017) Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer 116:21–27PubMedCrossRef
85.
Kiprian D, Jarzabski A, Kawecki A (2016) Evaluation of efficacy of Caphosol in prevention and alleviation of acute side effects in patients treated with radiotherapy for head and neck cancers. Contemp Oncol (Pozn) 20:389–393
Metadata
Title
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements
Authors
Noam Yarom
Allan Hovan
Paolo Bossi
Anura Ariyawardana
Siri Beier Jensen
Margherita Gobbo
Hanan Saca-Hazboun
Abhishek kandwal
Alessandra Majorana
Giulia Ottaviani
Monica Pentenero
Narmin Mohammed Nasr
Tanya Rouleau
Anna Skripnik Lucas
Nathaniel Simon Treister
Eyal Zur
Vinisha Ranna
Anusha Vaddi
Karis Kin Fong Cheng
Andrei Barasch
Rajesh V. Lalla
Sharon Elad
On behalf of The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO)
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04887-x

Other articles of this Issue 10/2019

Supportive Care in Cancer 10/2019 Go to the issue

Original Article

Adherence and quality of life in women with breast cancer being treated with oral hormone therapy

Original Article

Getting control during follow-up visits: the views and experiences of parents on tumor surveillance after their children have completed therapy for rhabdomyosarcoma or Ewing sarcoma

Original Article

Pruritus in patients with solid tumors: an overlooked supportive care need

Special Article

The pathogenesis of mucositis: updated perspectives and emerging targets

Original Article

Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy

Original Article

Cost-utility analysis of aprepitant for patients who truly need it in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits